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Abstract: The treatment of advanced stage, metastatic or recurrent endometrial cancer
remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an
effective standard-of-care regimen, alternate strategies have shown promise, particularly in
biomarker select populations. In an effort to improve oncologic outcomes, investigators are
exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale
and design of current phase III immuno-oncology clinical trials in patients with advanced stage
or recurrent endometrial cancer.
Keywords: antiangiogenic therapy, chemotherapy, combination therapy, endometrial cancer,
immune checkpoint inhibition, immunotherapy, tumor mutational burden
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Introduction
Endometrial cancer (EC) remains the only
gynecologic malignancy with a rising incidence
and mortality. In 2021, it is anticipated that
66,570 new cases of uterine cancer will be diagnosed in the United States, with approximately
12,940 deaths.1 Despite excellent outcomes in
patients with early-stage disease, those with metastatic or recurrent EC have limited options, representing an opportunity for therapeutic drug
development.
To date, combination carboplatin and paclitaxel
remains the preferred chemotherapy regimen in
the front-line treatment of EC. The Gynecologic
Oncology Group (GOG) 209 compared the combination regimen of paclitaxel and carboplatin to
paclitaxel, doxorubicin, and cisplatin (TAP) in
patients with stage 3, stage 4 or recurrent EC.
The study enrolled over 1300 patients and demonstrated less toxicity and a noninferior progression-free survival (PFS) and overall survival (OS)
with the doublet regimen, rendering paclitaxel
and carboplatin a suitable backbone for future
clinical trials.2

Second-line chemotherapy options for EC have
been historically less effective, although recent
advances show promise. Given the frequency of
phosphoinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) aberrations in
EC as well as the established importance of estrogen signaling in type I EC, Slomovitz and colleagues examined the combination of letrozole
and everolimus in a cohort of 38 patients with progressive or recurrent EC who had received up to
two prior chemotherapeutic regimens.3 A promising clinical benefit rate of 40% was identified with
a 32% objective response rate (ORR). Importantly,
patients with CTNNB1 mutations appeared to
respond particularly well to the drug combination
in exploratory translational studies.3
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An alternate biomarker-driven approach was
examined in a prospective phase II trial examining trastuzumab in combination with carboplatin
and paclitaxel in HER2/neu overexpressing uterine serous cancer.4 A total of 61 patients with primary stage III or IV or recurrent HER2/
neu-positive disease were enrolled on the trial.
Median PFS was 8.0 months in the control arm
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versus 12.6 months with addition of the antiHER2 agent [p = 0.005; hazard ratio (HR) 0.44;
90% confidence interval (CI), 0.26–0.76]. The
results of these two trials led to the National
Comprehensive Cancer Network compendium
listing of both letrozole plus everolimus as well as
the trastuzumab-containing regimen in the treatment of EC. More recently, Fader et al.5 reported
on OS, showing a striking benefit in patients with
stage 3 or 4 disease treated with trastuzumab in
combination with chemotherapy [24.4 months
(control) versus not reached (experimental),
p = 0.041, HR = 0.49, 90% CI 0.25–0.97].
Perhaps the greatest enthusiasm in the treatment
of patients with EC stemmed from the identification of immunotherapy as an effective treatment strategy. Catalyzed by the clinical
observation of one dramatic responder in two
separate colorectal cancer clinical trials, the efficacy of immunotherapy, particularly in mismatch-repair-deficient (dMMR) solid tumors,
was described in patients with colon cancer as
well as a mixed dMMR solid tumor population.6,7 These findings led to US Food and Drug
Administration (FDA) accelerated approval of
the anti-PD-1 antibody pembrolizumab (MK3475, Keytruda®) in May 2017 as monotherapy
in patients with dMMR or microsatellite instability-high (MSI-H) solid tumors, whose disease
has progressed following prior therapy, and
who have no satisfactory alternative treatment
options. This achievement represented the first
disease-site agnostic and histology independent
cancer drug approval, in which treatment is
based on a shared tumor biomarker rather than
on the anatomic site of origin.
The phase II Keynote-158 study ultimately
included 27 different tumor types, with endometrial, gastric, cholangiocarcinoma, and pancreatic
cancers being the most common.8 In the entire
population, the ORR was 34.3% (95% CI, 28.3–
40.8%), the median PFS was 4.1 months (95%
CI, 2.4–4.9 months) and the median OS was
23.5 months (95% CI, 13.5 months to not
reached). Within the EC cohort (n = 49), the
ORR was 57.1% (95% CI 42.2–71.2) and, importantly, the median OS and median duration of
response were not reached.8
Despite the above findings, and dramatic progress
in the dMMR/MSI-H populations, response to
single-agent checkpoint inhibition in mismatchrepair-proficient (pMMR) or microsatellite-stable
2

recurrent EC has been disappointing. As detailed
in several single-agent trials, response rates have
range from 6 to 13%, with short-lived PFS gains.9–
12 In an effort to improve response rates, and
oncologic outcomes in this patient population,
clinical trialists are examining novel combinatorial
approaches in conjunction with immune checkpoint inhibition. In this article, we will discuss the
current phase III clinical trial landscape as it
relates to immunotherapeutic regimens in the
treatment of EC, highlighting the clinical rationale
while discussing future drug development
opportunities.
Chemotherapy and immunotherapy
In order to improve on the number of patients
responding to checkpoint inhibitors, investigators
are assessing combination regimens involving
cytotoxic chemotherapy and PD-1/PD-L1 inhibition. Although no randomized controlled trials
comparing single-agent checkpoint inhibition to
combination regimens with cytotoxic agents have
reported in patients with gynecologic malignancies, preclinical data as well as emerging clinical
data support such an approach.13,14
Several preclinical studies have suggested that
cytotoxic chemotherapy may result in robust
immune stimulation14 (Table 1). Platinum
agents, including oxaliplatin, have been shown to
result in immunogenic cell death (ICD), producing a favorable milieu for immune activation
within tumor tissues.15 Furthermore, taxanes,
including docetaxel and paclitaxel, are known to
modulate the antitumor immune response. As an
example, concurrent paclitaxel therapy was
shown to significantly enhance radiation-induced
ICD in breast cancer cell lines.16 The antitumor
effects of cytotoxic chemotherapy may additionally be immunologic, with a reduction in regulatory T-cell activity and an enhanced presentation
of tumor cell-specific antigens.14,17,18 Cytotoxic
agents also appear to directly influence immune
checkpoint expression.19,20 Therefore, combining
chemotherapy and immunotherapy may lead to
enhanced antitumor effects.
Additional data supporting the investigation of a
combinatorial approach comes from the lung,
head and neck, as well as the breast cancer arena.
CheckMate 012 was conducted to explore the
safety and efficacy of nivolumab in combination
with current standard therapies in first-line
advanced non-small cell lung cancer (NSCLC).21
journals.sagepub.com/home/tam
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Table 1. Rationale for combinatorial approaches in the endometrial cancer space in an effort to expand
checkpoint inhibition beyond biomarker select populations.
Combination

Rationale

Immunotherapy + chemotherapy

Immune cell stimulation
Immunogenic cell death
Enhanced presentation of tumor-specific antigens
Increased T-cell activation by DCs

Immunotherapy + antiangiogenic Therapy

Reduction in Treg activity
Reversal of immunosuppressive effects of VEGF
Improved T-cell trafficking and infiltration of CD8+
T-cells and macrophages into the tumor bed
Increased immune cell recruitment

Immunotherapy + PARPi

Increased TILs
Enhance DNA damage, with increased CD8+ T-cells
Potential synergy with PARPi

DC, Dendritic Cells; PARPi, poly (ADP-ribose) polymerase inhibitor; TIL, Tumor Infiltrating Lymphocytes; Treg, regulatory
T-cell; VEGF, vascular endothelial growth factor.

The paclitaxel + carboplatin + nivolumab regimen was associated with a favorable toxicity profile, and median OS was not reached during
follow-up (range 8.8–30.1+ months).21 The most
common toxicities reported for the combination
were those anticipated with platinum doublet
therapy alone.21
In the phase II cohort of the open-label
Keynote-021 study, researchers enrolled a total of
123 patients with stage 3B/4 chemotherapy-naïve,
nonsquamous, NSCLC, to receive four cycles of
carboplatin and pemetrexed, with or without
24 months of treatment with pembrolizumab.22
Patients receiving pembrolizumab + chemotherapy exhibited a significantly greater ORR (55%
versus 29%, p = 0.0016) and an improved PFS (13
versus 8.9 months; HR 0.53; 95% CI 0.31–0.91).
Perhaps most strikingly, the incidence of potentially immune-mediated adverse events in the
pembrolizumab + chemotherapy group of the astreated population (22%), was similar to that
seen with pembrolizumab monotherapy in
Keynote-010 (20% in the 2 mg/kg cohort; 19% in
the 10 mg/kg cohort).
Lastly, in Keynote 189, a double-blind, randomized (2:1) phase III trial, 616 patients with
journals.sagepub.com/home/tam

NSCLC were randomized to receive platinum
chemotherapy and pemetrexed with pembrolizumab or placebo and up to 2 years of pemetrexed
maintenance with pembrolizumab or placebo.23
At a median follow-up of 10.5 months, the ORR
(47.6%, 95% CI, 42.6–52.5 versus 18.9% 95%
CI, 13.8–25.0; p < 0.001), PFS (HR 0.52; 95%
CI, 0.43–0.64; p < 0.001) and OS (HR 0.49;
95% CI, 0.38–0.64; p < 0.001) favored the pembrolizumab arm.23
There are currently four prospective, phase III clinical trials examining the impact of the addition of an
immune checkpoint inhibitor to standard 3-weekly
carboplatin + paclitaxel in patients with advanced
stage and recurrent EC (Table 2). NRG GY018
(ClinicalTrials.gov identifier: NCT03914612), was
designed to specifically evaluate the therapeutic
impact of pembrolizumab, when given in combination with chemotherapy in both pMMR and dMMR
cohorts in the front-line, adjuvant setting, or in
patients who completed adjuvant therapy
⩾12 months prior to study entry. Enrolled patients
are required to have central MMR immunohistochemistry (IHC) assessment prior to randomization, which will also permit correlation of local and
central testing results. Eligibility requirements
include measurable stage 3 or 4A disease as well as
3
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Table 2. Active phase III combination immunotherapy trials in patients with advanced stage and recurrent endometrial cancer.
Study

Drug regimen

Anticipated accrual

Study endpoint

NRG GY018
(NCT03914612)

Carboplatin + paclitaxel + placebo versus
Carboplatin + paclitaxel + pembrolizumab

N = 590 (pMMR)
N = 220 (dMMR)

Investigator-assessed
PFS

RUBY (NCT03981796)

Carboplatin + paclitaxel + placebo versus
Carboplatin + paclitaxel + dostarlimab

N = 470

Investigator-assessed
PFS

AtTEnd (NCT03603184)

Carboplatin + paclitaxel + placebo versus
Carboplatin + paclitaxel + atezolizumab

N = 550

Investigator-assessed
PFS and OS

Keynote 775
(NCT03517449)

Pembrolizumab + lenvatinib versus either
doxorubicin or paclitaxel (physician choice)

N = 770

BICR-assessed PFS

ENGOT-EN9/LEAP-001
(NCT03884101)

Pembrolizumab + lenvatinib versus
carboplatin + paclitaxel

N = 720

BICR-assessed PFS

DUO-E (NCT04269200)

Carboplatin + paclitaxel + placebo versus
Carboplatin + paclitaxel + durvalumab versus
Carboplatin + paclitaxel + durvalumab + olaparib

N = 699

Investigator-assessed
PFS

BICR, blinded independent central review; dMMR, mismatch repair deficient; NCT, ClinicalTrials.gov identifier; OS, overall survival;
PFS, progression-free survival; pMMR, mismatch repair proficient.

stage 4B or recurrent disease, irrespective of the
presence of a measurable lesion.
In an analogous manner, the RUBY trial
(ClinicalTrials.gov identifier: NCT03981796) is
randomizing patients with advanced stage or
recurrent EC to a carboplatin + paclitaxel backbone, with or without dostarlimab (IgG4 antiPD-1). Although similar in design, the RUBY
study permits enrollment of patients with carcinosarcoma histology and does not mandate a
minimum number of dMMR EC patients.
The AtTEnd trial (ClinicalTrials.gov identifier:
NCT03603184) was designed to determine if the
addition of atezolizumab (IgG1 anti PD-L1) to
carboplatin and paclitaxel, and then continued as
maintenance will translate into improved cancer
outcomes when compared to placebo in patients
with advanced stage or recurrent EC and measurable disease. It is anticipated that a total of 550
patients will be enrolled on study, with coprimary
endpoints of OS and PFS.
Lastly, DUO-E (ClinicalTrials.gov identifier:
NCT04269200), the most recently activated of
the above clinical trials, is a three-arm study that
expands the therapeutic question by adding
olaparib, an oral poly (ADP-ribose) polymerase
inhibitor (PARPi), to immunotherapy in the
maintenance setting (Table 2).There is mounting
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evidence to support the rationale of PARPi in
combination with immunotherapy. The accumulation of DNA errors in homologous recombination-deficient tumors, which appears to be
prevalent in EC, may result in somatic mutations
and neoantigen production triggering an immune
response.24,25 In fact, BRCA-mutated tumors
have been found to have an increased tumor
mutation burden, CD3+ and CD8+ immune cell
infiltration, and increased expression of PD-L1
and PD-1 in the intraepithelial and peritumoral
immune cell compartment compared to nonBRCA-mutated tumors.26
Antiangiogenic therapy and immunotherapy
In an effort to expand therapeutic options, cooperative group studies have explored antiangiogenic therapy with bevacizumab in patients with
advanced stage or recurrent EC. A single-arm
phase II study conducted by the GOG (GOG
229-E), examined bevacizumab at a dose of
15 mg/kg given intravenously every 3 weeks in
patients with persistent or recurrent EC and ⩽2
prior lines of chemotherapy.27 A total of 56
patients were enrolled, and although the response
rate was modest (13.5%), a promising 6-month
PFS rate of 40.4% was identified, with median
PFS and OS of 4.2 and 10.5 months, respectively.
Importantly, no gastrointestinal fistulae or perforations were reported on study (55.8% of patients

journals.sagepub.com/home/tam
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on GOG
therapy).

229-E

received

prior

radiation

There results prompted further investigation of
antiangiogenic therapy in this disease setting.
The therapeutic benefit of bevacizumab in the
front-line treatment of advanced stage, metastatic, or recurrent EC was examined in the
phase II GOG 86P study.28 This three-arm study
randomized 349 patients to either: (1) carboplatin
(C) + paclitaxel (P) + bevacizumab versus (2)
CP + temsirolimus versus (3) C + ixabepilone + bevacizumab. The CP + bevacizumab
triplet regimen compared favorably to the other
treatment arms, with a 59.5% ORR (24.7%
with complete response). In addition, when
compared to a matched group from the GOG
protocol 209 (CP arm), the triplet regimen of
CP + bevacizumab
showed
a
significant
improvement in OS (34 versus 22.7 months;
p < 0.039).28 Grade ⩾3 adverse events (AEs)
occurring in >5% of patients on the CP + bevacizumab regimen were limited to hypertension
and proteinuria. Furthermore, an Italian study
presented at the 2015 American Society of
Clinical Oncology annual meeting reported the
triplet regimen of CP + bevacizumab was superior to CP alone in patients with recurrent EC;
ORR 71.7 versus 54.3 %, median PFS 13 versus
8.7 months, median OS 23.5 versus 18 months,
respectively.29
There is a strong scientific and therapeutic rationale for combining immune checkpoint inhibitors
and antiangiogenic therapy (Table 1). Completion
and presentation of results from both the
IMpower150 (NSCLC) and IMmotion151 (renal
cancer) studies suggest added therapeutic efficacy
with the addition of atezolizumab (anti-PD-L1) to
a bevacizumab-containing regimen with acceptable
toxicity.30,31 Furthermore, results of the IMbrave150
trial (ClinicalTrials.gov identifier: NCT03434379),
results in US FDA approval of atezolizumab and
bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma who have not
received prior systemic therapy. The translational
and mechanistic rationale of this approach originally stemmed from data in the melanoma and
renal cell cancer arena. In an early study examining
the combination of ipilimumab (anti-CTLA-4)
and bevacizumab in patients with metastatic melanoma, Hodi et al.32 reported that on treatment
biopsies demonstrated increased CD8+ and macrophage cell infiltration in tumor beds. Additionally,

journals.sagepub.com/home/tam

extensive morphological changes were identified in
CD31+ endothelial cells, with widespread immune
cell infiltration on the combination regimen.
Additionally, Wallin et al.33 detailed, in a cohort
of 10 subjects with metastatic renal cell carcinoma treated on GP28328, that combination
atezolizumab and bevacizumab resulted in
increased intratumoral CD8+ T-cells, with a
related increase in intratumoral MHC-1, natural
killer cells, type 1 helper T-cells, T-effector markers and chemokines (CX3Cl1; fractalkine). These
synergistic effects are hypothesized to stem from
the proinflammatory impact of vascular endothelial growth factor (VEGF) blockade, as well as
hypoxia in the tumor microenvironment. Aside
from its direct antiangiogenic effects, bevacizumab may result in more robust antitumor
immunity by inhibiting VEGF-related regulatory
T-cell function while promoting immune cell
trafficking and T-cell priming/activation. Thus,
the combination regimen may enhance the immunogenic response in patients with advanced stage
or recurrent EC. Additionally, no concerning
safety signals have emerged across clinical trials
examining this therapeutic drug combination in
conjunction with cytotoxic chemotherapy.
Although no phase III studies have specifically
examined bevacizumab in combination with immunotherapy in the EC space, alternate multitargeted
antiangiogenic tyrosine kinase inhibitors have
shown significant promise. Lenvatinib is an oral
multikinase inhibitor that targets VEGF receptor-1–3, fibroblast growth factor receptor-1–4,
platelet-derived growth factor-α, and the oncogenes RET and KIT.34 Early phase II clinical trials
of lenvatinib, as monotherapy, in patients with
recurrent EC showed a response rate of 14%, with
a median PFS of 5.4 months (95% CI 8.8–21.4).35
In an effort to augment response, lenvatinib was
combined with pembrolizumab in a phase II,
open-label, single-arm, multicenter clinical trial
(study 111/Keynote 146).36 A total of 53 enrolled
patients were included in the analysis, with the
primary endpoint defined as the proportion of
patients with an objective response (complete or
partial response) at the week-24 tumor assessment as assessed by investigators according to the
immune-related Response Evaluation Criteria In
Solid Tumors. Eligible patients were aged 18 years
or older and had metastatic EC (unselected for
microsatellite instability or PD-L1 expression),
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had a good performance status, and no more than
two previous systemic therapies.36 The ORR was
39.6% (n = 21; 95% CI 26·5–54·0), although serious treatment-related AEs occurred in 16 (30%)
patients, and 1 treatment-related death was
reported (intracranial hemorrhage).36 The most
frequently reported any-grade treatment-related
AEs were hypertension (58%), fatigue (55%),
diarrhea (51%), and hypothyroidism (47%). The
most common grade 3 treatment-related AEs
were hypertension (34%) and diarrhea (8%).
At the 2019 European Society of Medical Oncology
meeting, Makker et al.37 presented updated outcomes data on a total of 108 EC patients treated
with the combination regimen. In the cohort of
patients who were not MSI-H or dMMR (n = 94),
the ORR was 38.9% (7.4% complete response
and 31.5% partial response; 95% CI 29.7–48.7).
Strikingly, although nearly half of the enrolled
patients had received two or more prior treatment
regimens, the median duration of response was
21.2 months (7.6 to not reached).37 Once again,
however, toxicity remained an issue with treatment-related AEs occurring in 105 (97%) of
patients (90% ⩽ grade 3, 7% ⩾ grade 4).
Treatment-related AEs led to study-drug interruption of one or both drugs in 78 (72%) patients
and resulted in dose reductions of lenvatinib in 70
(65%) patients on trial; 20 (19%) patients discontinued one or both drugs due to a treatmentrelated AE. Analogous to the earlier study, the
most common ⩾grade 3 AEs were hypertension
(32%), fatigue (8%), and diarrhea (7%).
Despite issues with tolerability, and the frequent
need for dose interruption or dose reduction,
these clinical findings reflected remarkable progress when compared to historical controls in the
EC space. On September 17, 2019, the US FDA
granted accelerated approval to the combination
of pembrolizumab plus lenvatinib for the treatment of patients with advanced EC that is not
MSI-H or dMMR and who have disease progression following prior systemic therapy but are not
candidates for curative surgery or radiation. This
approval was conducted under Project Orbis, and
allowed simultaneous review and approval in the
United States, Australia and Canada.
Subsequently, Keynote 775 was developed
(ClinicalTrials.gov identifier: NCT03517449)
(Table 2). This parallel, open-label, multicenter
phase III study randomized patients with recurrent EC, and at least one prior platinum-based
6

regimen, to receive either pembrolizumab and
lenvatinib or physician’s choice chemotherapy
(doxorubicin or paclitaxel), with a total target
accrual of 780 patients. The coprimary endpoints
of this trial are PFS (determined by blinded independent central review) and OS, with a recent
press release in December 2020, indicating that
the study met its dual primary endpoints, as well
as a key secondary endpoint of ORR.
Furthermore, the ENGOT-EN9/LEAP-001 study
(ClinicalTrials.gov identifier: NCT03884101) is a
phase III, randomized, open-label, active-controlled trial comparing combination therapy with
pembrolizumab and lenvatinib to carboplatin and
paclitaxel in patients with newly diagnosed stage
III–IV or recurrent EC (Table 2).38 Approximately
720 patients not previously treated with systemic
chemotherapy (except as part of a chemoradiation
regimen), antiangiogenic agents, PD-1 or PD-L1
inhibitors, or other T-cell receptor-targeted agents
will be randomized 1:1 to each arm. Patients will
be stratified by pMMR versus dMMR, and pMMR
patients will be further stratified by Eastern
Cooperative Oncology Group performance status
(0 versus 1), measurable disease (yes versus no),
and prior chemoradiation (yes versus no). This trial
may reflect a paradigm shift in EC therapeutics, as
the findings may lead to the replacement of cytotoxic chemotherapy in the front-line setting.
Conclusions
While identification of effective treatment strategies in the EC arena has been historically difficult,
tremendous gains have been realized with the
incorporation of immune checkpoint inhibitors.
To date, the greatest efficacy has been seen in the
dMMR or MSI-H populations, with the combination regimen of lenvatinib and pembrolizumab
showing synergistic effects in pMMR cohorts.
Translational studies accompanying contemporary trials will be important in helping inform
mechanisms of resistance and alternate treatment
opportunities. As detailed in the phase II
PHAEDRA trial, analysis of dMMR tumors that
failed to respond to checkpoint inhibition revealed
mutations of JAK1 or B2M, possibly reflecting
biallelic inactivation of these genes, which have
been associated with resistance.12 In parallel, trials
examining options in patients who have progressed after prior immune checkpoint inhibition,
particularly in the dMMR population, will be critical. Recently, Leureux and colleagues reported
journals.sagepub.com/home/tam

RN Eskander and MA Powell
on the combination of cabozantinib plus
nivolumab at the 2020 American Society of
Clinical Oncology virtual meeting.39 Although the
study size was small (n = 76), an exploratory
cohort of post-immune checkpoint inhibitor progressors was included, with three MSI-H patients
experiencing a response after prior progression on
single-agent nivolumab.
We eagerly await the results of the discussed
phase III clinical trials to determine whether
alternate drug combinations hold promise. It will
also be important to explore drug sequencing as
additional treatment options become available.
Certainly, the magnitude of benefit with the various combinations will inform treatment decisions
as we attempt to weigh oncologic gains against
treatment-related side effects.
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